Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02112214
PHASE3

Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population

Sponsor: National Cancer Center, Korea

View on ClinicalTrials.gov

Summary

The aim of this study is to define the role of H. pylori eradication in the prevention of gastric cancer and its precursors in the context of a population-based endoscopic screening program.

Official title: Effect of Helicobacter Pylori Eradication on Gastric Cancer Prevention in Korea: a Randomized Controlled Clinical Trial

Key Details

Gender

All

Age Range

40 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

5224

Start Date

2014-06

Completion Date

2029-12

Last Updated

2024-12-27

Healthy Volunteers

Yes

Interventions

DRUG

10-day bismuth-based quadruple therapy

Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days

OTHER

Placebo

Placebo for bismuth-based quadruple therapy

Locations (11)

Kosin University Gospel Hospital

Busan, South Korea

Pusan National University Hospital

Busan, South Korea

Hallym University Chuncheon Sacred Heart Hospital

Chuncheon, South Korea

Kyungpook National University Hospital

Daegu, South Korea

National Cancer Center

Goyang, South Korea

Chonnam National University Hospital

Gwangju, South Korea

Incheon St.Mary's Hospital/The Catholic University

Incheon, South Korea

Kandong Sacred Heart Hospital

Seoul, South Korea

SMG-SNU Boramae Medical Center

Seoul, South Korea

Chung-Ang University Hospital

Seoul, South Korea

Uijeongbu St. Mary's Hospital/The Catholic University

Uijeongbu-si, South Korea